Cargando…
SAT-119 Targeting Glutamate Metabolism and Signaling in ER+, Endocrine Therapy-Resistant Breast Cancer
Estrogen receptor-positive (ER+) breast cancer is the most commonly diagnosed form of this malignancy. Aromatase inhibitors and selective estrogen receptor modulators or degraders (SERMS, SERDs) can be highly effective in treating ER+ breast cancer, but de novo and acquired resistance to these inter...
Autores principales: | Olukoya, Ayodeji O, Stires, Hillary, Guerra, Yanira, Persaud, Sonali, Ma, Shihong, Raj, Ganesh V, Riggins, Rebecca B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207534/ http://dx.doi.org/10.1210/jendso/bvaa046.1086 |
Ejemplares similares
-
OR16-5 Riluzole suppresses growth and enhances response to endocrine therapy in ER+ breast cancer
por: Bahnassy, Shaymaa, et al.
Publicado: (2022) -
Riluzole Suppresses Growth and Enhances Response to Endocrine Therapy in ER+ Breast Cancer
por: Olukoya, Ayodeji O, et al.
Publicado: (2023) -
THU495 Glutamate Metabolic Enzymes GLUD1/2 And GPX4 Are Associated with Tumor Size In Black Women With Invasive Lobular Breast Cancer
por: Young, Todd, et al.
Publicado: (2023) -
SAT-LB310 A Mysterious Multiple Endocrine Neoplasia (MEN) Like Syndrome
por: Soe, Myat Han, et al.
Publicado: (2020) -
SAT-LB060 Clinical Presentation and Management of Primary Ovarian Carcinoids in Multiple Endocrine Neoplasia Type 1
por: Jhawar, Sakshi, et al.
Publicado: (2019)